U.S. Markets open in 8 hrs 48 mins

Novelos announces first enrollment in lung cancer trial with I-124-CLR1404

Novelos Therapeutics announced that the University of Wisconsin Carbone Cancer Center has enrolled the first patient in a Phase 1-2 positron emission tomography imaging trial of I-124-CLR1404, a cancer-targeted PET imaging agent, in patients with advanced non-small cell lung cancer.